ArticleAdvances in radiation oncology2026
Innovative and Customized 3-Dimensional-Printed Mold Brachytherapy Treatment of Genital Extramammary Paget's Disease.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: staged electron beam radiotherapy for inoperable primary ectopic abdominal extramammary Paget disease.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Extramammary Paget's disease (EMPD) is a rare intraepithelial neoplasm that affects apocrine gland-rich areas of the perineal region. Surgical treatment is the standard of care but is associated with significant morbidity. Nonsurgical options, such as surface mold brachytherapy (SMBT) with custom 3-dimensional (3D)-printed applicators, offer an innovative, organ-preserving alternative. Our aim was to evaluate the efficacy, safety, and cosmetic outcomes of custom 3D-printed SMBT in patients diagnosed with EMPD. Methods and Materials: A retrospective case series involving 9 patients treated for EMPD between November 2019 and April 2023 was included. Patient demographics, clinical characteristics, treatment parameters, and outcomes were analyzed. Primary outcomes included clinical response rates, acute and late toxicities (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5), and patient-reported cosmetic outcomes. Results: All 9 patients (6 men and 3 women) achieved a complete clinical response, with 1 patient experiencing marginal recurrence at 13.6 months posttreatment. Acute grade 3 dermatitis occurred in all patients and resolved, on average, within 54 days (range, 35-72). Late toxicities included hypopigmentation (4 patients) and telangiectasia (3 patients). Cosmetic outcomes were rated as excellent or very good by 89% of patients. Conclusions: This study represents the first report on the use of custom 3D-printed SMBT for EMPD. This technique demonstrates excellent local control, manageable toxicity, and favorable cosmetic outcomes, offering a promising alternative to surgery in this anatomically complex area.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.